Myeloid Leukemia News and Research

RSS
Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Formaldehyde exposure not linked to leukemia, research shows

Formaldehyde exposure not linked to leukemia, research shows

Scientists launch new virtual platform to aid global search for treatment of leukemia

Scientists launch new virtual platform to aid global search for treatment of leukemia

FDA approves new drug and chemotherapy combination for treatment of adult patients with AML

FDA approves new drug and chemotherapy combination for treatment of adult patients with AML

Second cancers are far deadlier in younger people than older adults

Second cancers are far deadlier in younger people than older adults

Global inequalities in survival for childhood leukemia still persist in some countries, study finds

Global inequalities in survival for childhood leukemia still persist in some countries, study finds

Scientists discover potential trigger for MDS in children with rare genetic disorder

Scientists discover potential trigger for MDS in children with rare genetic disorder

Scientists show p300 protein may stop MDS from developing into leukemia

Scientists show p300 protein may stop MDS from developing into leukemia

FDA approves new maintenance therapy for recurrent cancers

FDA approves new maintenance therapy for recurrent cancers

Study identifies potential Achilles heel of kinase-driven cancers

Study identifies potential Achilles heel of kinase-driven cancers

New study correlates 80 cancer-related gene mutations with 34 AML subgroups

New study correlates 80 cancer-related gene mutations with 34 AML subgroups

Early death from pediatric cancer subtypes more likely to happen than previously reported

Early death from pediatric cancer subtypes more likely to happen than previously reported

Research findings could guide development of potent combination therapies for leukemia

Research findings could guide development of potent combination therapies for leukemia

Clinical study seeks to examine new combination therapy for treating AML patients

Clinical study seeks to examine new combination therapy for treating AML patients

Study establishes ENL protein as potential drug target for acute myeloid leukemia

Study establishes ENL protein as potential drug target for acute myeloid leukemia

Researchers looking at ways to target lingering cancer stem cells that cause disease relapse

Researchers looking at ways to target lingering cancer stem cells that cause disease relapse

GUMC launches phase II clinical study to examine safety of cancer drug for Parkinson's disease

GUMC launches phase II clinical study to examine safety of cancer drug for Parkinson's disease

Fred Hutch scientists make important step in identifying specific T cells to fight against cancer

Fred Hutch scientists make important step in identifying specific T cells to fight against cancer

Targeting tumor suppressor protein could be effective treatment for some AML patients, study suggests

Targeting tumor suppressor protein could be effective treatment for some AML patients, study suggests

Young adults, adolescents with acute leukemia treated at specialized cancer centers have higher survival rates

Young adults, adolescents with acute leukemia treated at specialized cancer centers have higher survival rates

Researchers create novel model that reveals cellular, molecular events driving leukemia progression

Researchers create novel model that reveals cellular, molecular events driving leukemia progression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.